Ivarmacitinib治疗中重度特应性皮炎:3期随机临床试验
该多中心双盲安慰剂对照3期试验纳入336例12-75岁中重度特应性皮炎患者,随机接受每日一次4mg或8mg Ivarmacitinib或安慰剂治疗16周。结果显示两种剂量在IGA 0/1应答率和EASI-75应答率上均显著优于安慰剂,不良事件发生率与安慰剂相近,支持其作为新治疗选择。
要点
- Ivarmacitinib 4mg和8mg组第16周IGA 0/1应答率分别为36.3%和42.0%,显著高于安慰剂9.0%。
- EASI-75应答率在4mg组为54.0%、8mg组为66.1%,均显著高于安慰剂21.6%。
- 治疗中出现的不良事件发生率三组相近,严重不良事件少见。
核心结论
- 每日一次Ivarmacitinib对成人和青少年中重度特应性皮炎具有显著疗效和良好的风险获益特征。
研究设计与样本
- 多中心、双盲、安慰剂对照3期随机临床试验,纳入12至75岁中重度特应性皮炎患者336例。
- 患者来自加拿大和中国53个中心,2021年4月至2022年4月入组,按1:1:1随机接受每日一次4mg或8mg Ivarmacitinib或安慰剂治疗16周。
主要发现
- 第16周IGA 0/1且较基线改善至少2级的患者比例:4mg组36.3%(95%CI 27.5%-45.9%,P<.001),8mg组42.0%(95%CI 32.7%-51.7%,P<.001),安慰剂组9.0%(95%CI 4.4%-15.9%)。
- 第16周EASI-75应答率:4mg组54.0%(95%CI 44.4%-63.4%,P<.001),8mg组66.1%(95%CI 56.5%-74.8%,P<.001),安慰剂组21.6%(95%CI 14.4%-30.4%)。
- 治疗中出现的不良事件发生率:4mg组69.0%(78例),8mg组66.1%(74例),安慰剂组64.9%(72例);严重治疗中出现的不良事件发生率分别为2.7%(3例)、1.8%(2例)和2.7%(3例)。
临床怎么用
- 对于中重度特应性皮炎的成人和青少年患者,每日一次口服Ivarmacitinib 4mg或8mg可作为潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Ivarmacitinib, a selective oral Janus kinase 1 (JAK1) inhibitor, has demonstrated efficacy for treating adults with moderate to severe atopic dermatitis (AD) in a phase 2 trial. OBJECTIVE: To evaluate the efficacy and adverse events of ivarmacitinib in adolescents and adults with moderate to severe AD. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial included patients aged 12 to 75 years with moderate to severe AD. Patients were enrolled from 53 sites in Canada and China from April 2021 to April 2022. Data were analyzed from July 11 to September 27, 2023. INTERVENTIONS: Patients were randomized (1:1:1) to receive once-daily 4- or 8-mg ivarmacitinib or placebo for 16 weeks. MAIN OUTCOMES AND MEASURES: Co-primary end points were the proportions of patients achieving an Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline and an Eczema Area and Severity Index score improvement of 75% (EASI-75) at week 16. RESULTS: Of 336 randomized patients (mean [SD] age, 31.1 [15.4] years; 213 [63.4%] male; 286 [85.1%] Asian), 113 received 4-mg ivarmacitinib, 112 received 8-mg ivarmacitinib, and 111 received placebo. At week 16, significantly more patients in the 4-mg ivarmacitinib group (41 of 113 [36.3%]; 95% CI, 27.5%-45.9%; P < .001) and the 8-mg ivarmacitinib group (47 of 112 [42.0%]; 95% CI, 32.7%-51.7%; P < .001) achieved an IGA score of 0 or 1 with at least a 2-grade improvement compared to the placebo group (10 of 111 [9.0%]; 95% CI, 4.4%-15.9%). EASI-75 responses were also significantly higher in the ivarmacitinib groups: 61 patients (54.0%; 95% CI, 44.4%-63.4%; P < .001) in the 4-mg group, and 74 (66.1%; 95% CI, 56.5%-74.8%; P < .001) in 8-mg group compared to 24 patients (21.6%; 95% CI, 14.4%-30.4%) in the placebo group. Treatment-emergent adverse events were reported by 78 patients (69.0%) in the 4-mg group, 74 (66.1%) in the 8-mg group, and 72 (64.9%) in the placebo group. Serious treatment-emergent adverse events occurred in 3 patients (2.7%) in the 4-mg group, 2 (1.8%) in the 8-mg group, and 3 (2.7%) in the placebo group. CONCLUSIONS AND RELEVANCE: This phase 3 randomized clinical trial determined that once-daily ivarmacitinib demonstrated significant efficacy and a favorable risk-benefit profile for treating moderate to severe AD in adults and adolescents. These results support the potential of ivarmacitinib as a new therapeutic option. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04875169.
引用
- Zhao Y, Gooderham M, Yang B, et al. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents: A Phase 3 Randomized Clinical Trial. JAMA Dermatol. 2025. PMID: 40305055. doi:10.1001/jamadermatol.2025.0982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。